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Background: PTP4A3 is a subclass of a protein tyrosine phosphatase super family and 
is expressed in a range of epithelial neoplasms. We evaluated PTP4A3 expression and its 
association with clinical-pathological parameters in different types of functioning 
pituitary adenomas.  
Methods: A total of 34 functioning pituitary adenomas samples were evaluated in this 
observational study. PTP4A3 expression was examined by immunohistochemical 
staining, and, possible correlations between PTP4A3 and some clinical-pathological 
variables were investigated. 
Results: PTP4A3 was expressed in 19 out of 34 tumors (55%), at the cytoplasmic level 
of tumoral cells. Moreover, there was significant association (p=0.042) between PTP4A3 
expression and tumoral size. 
Conclusions: PTP4A3 was expressed in more than half of the tumors analyzed, with there 
being a significant association with the tumoral size of functioning adenomas. This allows 
to speculate that PTP4A3 may regulate tumor growth, although further investigations are 
necessary to determine if this phosphatase can serve as a biomarker or used as a 

















The pituitary adenomas are one of the most frequent intracranial tumors, 
accounting for 10% of these and also 90% of intrasellar lesions with a prevalence of 
1/1500, with approximately half of these tumors being functioning (46%–64%).1,2,3 
Although pituitary adenomas are histologically benign, some may grow and become 
locally aggressive, resulting in a shortened lifespan.4,5 Different types of functioning 
pituitary adenomas are currently treated by medical therapies such as dopamine and 
somatostatin agonists, surgery or radiotherapy. However, these treatments are not entirely 
satisfactory and patients can fail to respond to traditional approaches.6 
Protein tyrosine phosphatases (PTPs) are a large family of enzymes that catalyze 
the removal of phosphate groups attached to the tyrosine residues on their substrates, and 
are essential for regulating a myriad of cellular processes. 7 In the tumoral pituitary gland, 
classical PTPs are considered to be cell growth regulators.8 Protein Tyrosine Phosphatase 
4A3 (PTP4A3, also known as PRL-3) belongs to this group and has been implicated in 
the control of cell cycle, survival, angiogenesis, adhesion, cytoskeleton remodeling, 
epithelial-mesenchimal transition, motility and invasion.10 Moreover, PTP4A3 is a 
growth-associated protein in some tumoral types, with many studies having identified  
PTP4A3 to be a marker of tumor progression in different neoplasms. 11-14 Although an 
increased PTP4A3 expression, both at the mRNA and protein level, has been reported in 
several solid tumors, its expression in functioning pituitary adenomas has not yet been 
investigated. 
Recently, a humanized antibody, PRL3-zumab, was shown to inhibit PTP4A3+ 
cancer cells in vivo, and thus this represents a feasible approach for anti-tumor 
immunotherapy.15 Taking into consideration this finding and that new therapeutic targets 
in functioning pituitary adenomas are required for improved endocrinological treatments,  
we performed an observational descriptive study of PTP4A3 expression in 34 




Patients and Samples 
A transsphenoidal surgery was performed on all sellar tumors, and the inclusion 
and exclusion criteria are shown in Table 1. 
An observational, descriptive and retrospective study of normal pituitary glands 
(n:2; 30 min postmortem, aged 25-45, patients with no evidence of endocrine or 
histological abnormalities) and functioning pituitary adenomas of 34 adults (aged 20-64 
years) was conducted at the Centro de Microscopía Electrónica-INICSA-Conicet.  
Patients had undergone surgery at Hospital Córdoba, Sanatorio Allende or Clínica 
Reina Fabiola, Córdoba, Argentina between the years 2004-2015. These institutions 
performed the clinical diagnosis and reticulin staining, hormone analysis and Ki67 
immunohistochemistry characterization, and also provided the samples in paraffin blocks.  
The following data were collected: sex, age, tumoral size 
(macroadenoma/microadenoma), invasion, previous medical treatment, histopathology, 
hormone staining and Ki67 labeling index (Table 2).  
 
Immunohistochemical staining 
Sections 3μm thick were obtained from 34 functional pituitary adenomas and 
processed for immunohistochemistry. Briefly, the samples were deparaffinized in xylene 
and hydrated in alcohols, and the sections were heated in a microwave for 15 min in a 
citrate buffer (pH 6.0). Next, the sections were incubated first with hydrogen peroxide 
0.5% solution in methanol to block endogenous peroxidase, and then with PTP4A3 rabbit 
polyclonal antibody (Abcam to anti-PTP4A3 ab82568, USA. 1/70) overnight at 4°C, and 
finally with biotinylated anti-rabbit antibody with ABC complex (Vector Laboratories, 
Burlingame, CA, USA). The reaction was detected using DAB as chromogen (Sigma, St. 
Louis, MO, USA). Positive controls for PTP4A3 were performed in human colon 
adenocarcinoma, with negative controls carried out by omitting the primary antibody 
incubation. The number of positively stained cells in the human adenomas was 
determined in 10 random fields at 400X. The total number of positive cells as a proportion 
of the number of cells in the field of vision was used to assign positive or negative values. 
If the percentage of positive cells was ≤10%, this was recorded as  "0"; a percentage of 
between 11% and 25% was assigned "+"; a value of 26% -50% was recorded as "++";  a 
percentage of 51% -75% was assigned "+++" and finally, a value > 76% was recorded as 
"++++".   
 
Western blot analysis 
Protein extracts (50 μg) from 2 normal pituitary and 3 functioning pituitary 
adenomas (macro non-invasive corticotroph adenoma, macro invasive somatrotroph 
adenoma and macro invasive lactotroph) were separated in a polyacrylamide gel (Sigma–
Aldrich), transferred to a nitrocellulose membrane (Amersham International), and the 
nonspecific binding was blocked with PBS-5% non-fat dried milk at RT. The membranes 
were then rinsed and incubated overnight with anti-PTP4A3 (Abcam to anti-PTP4A3 
ab82568, USA) (1:166) or anti--Actin (1:4000; Sigma–Aldrich). The blots were 
incubated with HPRT-conjugated bovine anti-goat (1:2500; Santa Cruz Biotechnology), 
goat anti-mouse (1:2500, Jackson ImmunoResearch) or goat anti-rabbit secondary 
antibodies (1:5000, BioRad). The membranes were thoroughly rinsed in TBS 0.1% 
Tween 20, and the HPRT-coupled secondary antibody was revealed using enhanced 
chemiluminescence Western blotting detection reagents (GE Healthcare), with the 
emitted light captured on Hyperfilm (GE Healthcare). 
 
Statistical analyses 
Data were presented as mean (SD) for continuous data or for frequency and 
percentages (categorical data). We estimated the 95% confidence interval for the main 
quantitative variables. The T-test was used to compare PTP4A3 and the Ki67 labeling 
index between tumoral sizes (macroadenoma vs microadenoma). The Fisher exact test 
was used to assess an association between invasion and tumor size, a p value <0.05 was 
considered to be statistically significant for all the analyses. The statistical analysis was 
performed using the Stata 15.1 statistical package.16 
 
RESULTS 
PTP4A3 expression in functional pituitary adenomas  
Pituitary adenomas were characterized by the H/E stain, immunohistochemistry 
hormone determination and transmission electron microscopy (figure 1A-D). In this 
cohort, 59% of patients were female, with the mean (SD) age being 39 (12.96) years.  
The clinico-pathological findings revealed that there were 29% lactotroph cell 
adenomas, 20% somatotroph adenomas, 11% mammosomatotropic adenomas, 35% 
corticotroph cell adenomas and 3% tirotroph cell adenomas (figure 1). Of the above, 56% 
were macroadenomas and 44% microadenomas. As 4 of the lactotroph cell adenomas 
were resistant to previous medical treatment (dopamine agonist), these were treated 
surgically.   
The mean (SD) of the Ki67 index was 2.68 (0.39); CI 95% [11.88-3.48]. Sixty-
eight percent of the adenomas revealed a Ki67 index equal to or less than 3%, with the 
Ki67 index being independent of tumor size (p > 0.05). Unfortunately, the presence or 
absence of invasion could only be determined in 10 out of 34 functional pituitary 
adenomas. 
The PTP4A3 expression in 34 functioning pituitary adenomas was determined by 
immunohistochemistry, with the mean (SD) of PTP4A3 being 23.02857 (4.72); CI 95% 
[13.42- 32.62]. As shown in Figure 1-F, PRL-3 protein was mainly localized in the 
cytoplasm, which sometimes occurred as granulated loci in the strongly positive samples. 
According to the criteria, the PTP4A3 positive expression rate was 64% in the adenoma 
group (Table 3). The semi-quantitative phosphatase analysis showed that there was a 
higher expression of PTP4A3 in proliferative pituitary lesions than in normal glands 
(figure 1-I). However, there was only a significant and greater difference found for 
PTP4A3 between pituitary macro adenomas and micro adenomas (p=0.042) (Table 4). 
Finally, for the adenoma pituitary linage-cells, the PTP4A3 expression was similar in the 
PRL-STH-TSH (54%) linage and ACTH linage (58%).  
 
DISCUSSION 
Functioning pituitary tumors are benign proliferations with different biological 
characteristics and behaviors, especially with regard to tumor size and invasion.4 Similar 
to other series reported, in our cohort 59% of patients were female, but the mean age was 
about 39 years lower than for other studies.3 Women were predominant and at an earlier 
age and most markedly for corticotroph tumors, as was previously reported.3 
We conducted an observational descriptive study to evaluate PTP4A3 expression 
in the normal pituitary gland and in a functioning adenoma cohort. This phosphatase is in 
normal tissue mainly expressed in the heart, skeletal muscle, and to a lesser extent in the 
prostate.9 PTP4A3 also shows low basal levels in the human normal pituitary gland in 
agreement with that the fact that phosphatase is expressed at low levels in other normal 
human epithelial tissue. 9 However, this PTP has largely unknown physiological cellular 
functions, although it has been associated with terminal cell differentiation as well as 
appearing to be important in ensuring cell cycle progression by facilitating G1⁄S 
transition.9,17 
In our investigation, 19 out of 34 functioning pituitary adenomas exhibited 
detectable immunolabeling of PTP4A3, with 26% to 50% of the immunopositive cells 
occurring in more than half of PTP4A3 positive adenomas. One important point was that 
63.63% of somatotroph adenomas, 58.33% of corticotroph adenomas and 50 % of 
lactotroph adenomas were PTP4A3 positive tumors. To date, few pituitary investigations 
have reported PTPs’ expression. It has been proposed that the ‘classical PTPs’, namely 
SHP-1, SHP-2, and DEP-1/PTPn, play a pivotal role in SRIF/SRL-mediated control of 
cell growth, and seem to be activated by ligand-binding to all the different SST subtypes. 
Cells transfected with the individual somatostatin receptor (SSTR) subtypes have 
demonstrated that all the 5 SSTRs are able to induce PTP activity. 8,18 However, we report 
for first time a PTP4A3 increased expression in a group of different cell linage pituitary 
adenomas. Although no substrate has yet been clearly identified for the PTPs, a few have 
been suggested for PTP4A3, such as the PI3K-Akt pathway, although the direct 
mechanism involved still remains unclear.19 
Monsalves et. al. suggested that the pituitary adenoma growth rate is influenced 
by various patient- and tumor-specific characteristics, such as age, sex, specific subtype, 
hormonal activity and immunohistochemical profile, including the mindbomb homolog 
1 labeling index status.20 Here, we demonstrated that there was significant difference 
between PTP4A3 expression and pituitary adenoma size, thereby revealing a possible 
new molecule that may regulate tumor growth, at least in some adenomas. We also 
consider that our findings have identified a new concept in pituitary pathology, in which 
a group of PTP4A3 positive macroadenomas could be a potential therapy target for new 
treatments to reduce the tumoral size, and may be also utilized as a postoperative adjuvant 
therapy to prevent recurrence.15 Although we cannot extrapolate the results to fit the entire 
population (inclusive bias), a further multicenter study with a large sample size should be 
conducted, to determine if PTP4A3 immunostaining could also be used to identify 
potential patients as a PRL3-zumab target. 
 
Take home messages 
→ PTP4A3 is expressed in the normal pituitary gland. 
→ Overexpression of PTP4A3 was observed in a series of 19 patients with pituitary 
adenomas, with phosphatase expression occurring in the PRL-GH-TSH linage and 
ACTH-linage cells. 
→ There was a significant difference between PTP4A3 expression in pituitary macro 
adenomas vs. micro adenomas. 
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Figure 1 Ultrastructure and hormone immunolabeling in lactotroph (A), somatrotroph 
(B), coticotroph (C) and tirotroph (D) adenomas. E-Negative control of PTP4A3 
immunolabeling in pituitary adenomas; F: PTP4A3 expression, mainly localized in the 
cytoplasm (x400, magnification). G: +++ PTP4A3 expression, H: Positive PTP4A3 
control in colon cancer sample. Inset: negative control omitting primary antibody. I: 



































Table 1 Patient inclusion and exclusion criteria 
Patient inclusion criteria 
- Female and male patients older than 18 years old 
- Functioning pituitary adenomas 
- Availability of clinical data (previous medical treatment medical, tumoral size, tumoral 
invasion) 
- Availability of immunolabelling report of adenohypophyseal hormones and Ki67 
Patient exclusion criteria 
- Sellar non-pituitary adenomas (neuronal and paraneuronal tumors; mesenchymal 
tumors; germ cell tumors; hematological tumors; secondary tumors) 














Table 2 Clinical variables and pathological parameters  
 







1 M 59 M Yes Naive to treatment Sparsely granulated lactotroph adenoma PRL 8 
2 M 51 M Yes Naive to treatment Sparsely granulated lactotroph adenoma PRL 1 
3 F 30 M NA Naive to treatment Sparsely granulated lactotroph adenoma PRL 1 
4 M 27 M NA Naive to treatment Sparsely granulated lactotroph adenoma PRL 10 
5 M 35 M Yes Naive to treatment Sparsely granulated lactotroph adenoma PRL 5 
6 M 60 M NA Naive to treatment Sparsely granulated lactotroph adenoma PRL 5 
7 F 20 m NA Resistant Sparsely granulated lactotroph adenoma PRL 1 
8 F 38 m NA Resistant Sparsely granulated lactotroph adenoma PRL 1 
9 F 31 m NA Resistant Sparsely granulated lactotroph adenoma PRL 1 
10 F 26 m NA Resistant Sparsely granulated lactotroph adenoma PRL 1 
11 M 57 M NA Naive to treatment Densely granulated somatotroph adenoma STH 2 
12 F 33 M Yes Naive to treatment Densely granulated somatotroph adenoma STH 1 
13 F 64 M NA Naive to treatment Sparsely granulated somatotroph adenoma STH 0 
14 F 49 M NA Naive to treatment Sparsely granulated somatotroph adenoma STH 1 
15 M 29 M NA Naive to treatment Sparsely granulated somatotroph adenoma STH 3 
16 F 58 m NA Naive to treatment Densely granulated somatotroph adenoma STH 3 
17 M 37 m NA Naive to treatment Sparsely granulated somatotroph adenoma STH 2 
18 F 35 M NA Naive to treatment Mammosomatotroph adenoma STH/PRL 4 
19 M 28 M NA Naive to treatment Mammosomatotroph adenoma SHT/PRL 2 
20 M 53 m NA Naive to treatment Mammosomatotroph adenoma SHT/PRL 5 
21 F 41 m NA Naive to treatment Mammosomatotroph adenoma STH/PRL 1 
22 M 32 m No Naive to treatment Thyrotroph adenoma TSH 5 
23 M 35 M Yes Naive to treatment Densely granulated corticotroph adenoma ACTH 1 
24 F 32 M NA Naive to treatment Densely granulated corticotroph adenoma ACTH 5 
25 F 62 M Yes Naive to treatment Densely granulated corticotroph adenoma ACTH 2 
26 F 51 M NA Naive to treatment Densely granulated corticotroph adenoma ACTH 3 
27 F 31 M NA Naive to treatment Densely granulated corticotroph adenoma ACTH 2 
28 F 41 M NA Naive to treatment Densely granulated corticotroph adenoma ACTH 2 
29 F 55 m No Naive to treatment Densely granulated corticotroph adenoma ACTH 0 
30 F 23 m No Naive to treatment Densely granulated corticotroph adenoma ACTH 3 
31 M 30 m No Naive to treatment Densely granulated corticotroph adenoma ACTH 3 
32 F 21 m NA Naive to treatment Densely granulated corticotroph adenoma ACTH 1 
33 F 25 m NA Naive to treatment Densely granulated corticotroph adenoma ACTH 7 




Gender: M: male, F: female; Size: M: macroadenoma, m: microadenoma; Invasion: NA: not 












Table 3 PTP4A3 expression in pituitary adenomas 
Adenoma n Neg 1+ 2+ 3+ 4+ 
PRL 10 5 2 2 0 1 
GH 11 4 3 4 0 1 
TSH 1 1 0 0 0 0 





















Table 4 Relationship of PTP4A3 positive expression and pituitary adenomas  
 clinico-pathological features 
 
    PRL-3 positive expresssion 
Clinical Data n Positive Percentage 
    (Cases) (%) 
Age    
>55 9 3 33,33 
<55 25 16 64 
Gender    
men 13 8 61,53 
women 21 11 52,38 
Adenoma     
PRL 10 5 50 
GH 11 7 63,63 
TSH 1 0 0 
ACTH 12 7 58,33 
Tumoral Size    
Macro 19 13 68,42 
Micro 15 6 40 
 
 
 
